GSK

That's a wrap on #ASCO26! We're proud of our oncology progress. Our existing portfolio is focused on creating a positive impact and our R&D pipeline aims to bring more innovative medicines to patients. Watch our oncology leaders, Hesham Abdullah and Ali Çimen, reflect on an inspiring weekend ⤵️

Have you heard of antibody-drug conjugates (ADCs)? These innovative therapies are becoming a promising option for more targeted cancer treatment, and our researchers are at the forefront of advancing their potential. Curious to learn more? 🔗 Hear from our leading experts: bit.ly/42ZvUTd

#News for #investors & #media: Today at #EASLCongress, we’re presenting results from a phase III trial in chronic hepatitis B, a disease affecting approximately 240 million people globally. Learn more: gsk.to/3S77yoc

#News for #investors and #media: We're excited to be at #ASCO26 and #EHA2026, where we will share data on how we're delivering a meaningful impact for cancer patients today while innovating for tomorrow. Learn more: gsk.to/49hUlis

#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been approved for an expanded population by the Japanese Ministry of Health, Labour and Welfare (MHLW). Learn more: gsk.to/4eSI47M

At our recent virtual event with Washington Post Live Hesham Abdullah, Global Head of Oncology R&D at GSK and Peter Lee, President of Microsoft Science, shared how cutting-edge technology is fuelling the mission to improve outcomes for people living with cancer – and to do so more quickly.

#News for #investors and #media: At #ATS2026, we’ll be presenting data across 33 abstracts to highlight our research as we work to redefine respiratory care. gsk.to/4nmDlx9

News for #Investors and #Media Watch our CEO Luke Miels as he shares our strong Q1 performance and start to 2026 ⤵️ Find out more: gsk.to/4ePgo3m $GSK #earnings

#News for #investors and #media: Today we are announcing that our potential treatment for chronic hepatitis B has been accepted for regulatory review by US FDA. Learn more: gsk.to/3Qz28Sq

#News for #investors and #media: Today we announced that our investigational liver therapy received US FDA Breakthrough Therapy and EMA Priority Medicine (PRIME) regulatory designations for metabolic dysfunction-associated steatohepatitis (MASH). Find out more: gsk.to/3Qp3P4V

Symptoms of CRSwNP, like nasal obstruction, facial pain and sleep disturbances, can greatly impact a person’s quality of life. Today, on #WorldCRSwNPDay, we’re reinforcing our commitment to improving patient outcomes. See how: gsk.to/4twp830

#News for #Investors and #Media China’s National Medical Products Administration (NMPA) has approved our therapy to treat an incurable and challenging blood cancer. For more information, visit: gsk.to/3QPIamj

#News for #investors and #media: Today we announced the completion of our acquisition of 35Pharma Inc., adding to our Respiratory, Immunology & Inflammation pipeline. Find out more: gsk.to/4ccpQw3

#News for #Investors and #Media: Today at #SGO2026, we’re presenting new data on an investigational antibody-drug conjugate from our oncology pipeline. Learn more: gsk.to/3Q00jh7

We're at #SGO26! With an innovative pipeline, we’re building on our strong foundations in oncology research to improve how people live with cancer 🧡 Join us as we share more about our vision for transforming cancer care. 🔗 Learn more: bit.ly/4dz0866

#News for #Media and #Investors: China's National Medical Products Administration (NMPA) has approved our new therapy for people living with chronic rhinosinusitis with nasal polyps (CRSwNP). For more information, visit: bit.ly/43sHkQ0

#News for #investors and #media: Today we are announcing that our potential treatment for chronic hepatitis B has been accepted for regulatory review in China. Learn more: gsk.to/4uZos7p

#News for #Media and #Investors: China’s National Medical Products Administration (NMPA) has approved our new therapy for the treatment of severe asthma. For more information, visit: gsk.to/47tXAlQ

#News for #investors and #media: Today we are announcing that our potential first-in-class treatment for chronic hepatitis B has been accepted for regulatory review by the EMA. Learn more: gsk.to/489nuvm

#News for #Investors and #Media: Today we announced that Japan’s Ministry of Health, Labour and Welfare has granted Orphan Drug Designation to an investigational antibody-drug conjugate in our oncology pipeline. Learn more: gsk.to/4sZtdvP

#News for #investors and #media: Today, we are announcing that one of our liver medicines has been approved by the US Food and Drug Administration (FDA). Find out more: gsk.to/4bHlfke

Published today, our latest Annual Report and Responsible Business Report show our progress in creating value for patients and shareholders. Take a look at the highlights ⤵️ 🔗 Investors and media can read more: gsk.to/4rTabHu

Today we’re at #SLEuro discussing the importance of early intervention and its role in reducing the risk of organ damage progression for patients with lupus and lupus nephritis.

#News for #investors and #media: Today we announced the completion of our acquisition of RAPT Therapeutics, adding to our growing Respiratory, Immunology & Inflammation (RI&I) pipeline. Find out more: gsk.to/4bjpC5H

#News for #investors and #media: Today we are announcing our potential treatment for chronic hepatitis B has been accepted for regulatory review in Japan. Learn more: gsk.to/3MKpqTS

News for #Investors and #Media: Today at #CROI2026, our specialist HIV company ViiV Healthcare, presented new insights on our investigational long-acting therapies. 🔗 Find out more on our website: gsk.to/4sfUv0S

#News for #investors and #media: We’ve announced an agreement to acquire 35Pharma. Find out more: gsk.to/3ZS9thp

News for #Investors and #Media: New data published in the New England Journal of Medicine compare efficacy of different forms of HIV treatment for people with adherence challenges. 🔗 Find out more on our website: gsk.to/40fqNNh

#News for #Investors and #Media: Today we are presenting new data about one of our vaccines. Learn more: gsk.to/4bZNQ66

#News for #investors and #media: The European Commission has approved our new therapy to treat two respiratory diseases. Learn more here: gsk.to/4tzOptr

#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been accepted for review by the China National Medical Products Administration. Learn more: gsk.to/4qnf6Pd

Tuberculosis is a serious and contagious lung disease, with 10 million people worldwide falling ill with it each year. New treatment options are needed, and research collaborations like our work with @dundee.ac.uk are essential to keep innovation at the forefront in the fight against TB.

#News for #investors and #media: We have announced that the European Commission has approved a new therapy for use in adults with chronic obstructive pulmonary disease (COPD). Learn more here: gsk.to/3O0TpXN

Today we announce our strong 2025 performance, driven mainly by Specialty Medicines, and reaffirm our long-term outlooks. Hear more from our CEO Luke Miels ⤵️ More information for media and investors: gsk.to/4r7A5qv $GSK #earnings

Today on #WorldNTDDay, we’re reinforcing our commitment to helping eliminate neglected tropical diseases (NTDs) through our new three-year project with the END Fund. Their expertise means they are ideally placed to deliver this project, helping towards eliminating NTDs 🙌#UniteActEliminate #EndNTDs

#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been approved for an expanded indication by the European Commission (EC). Learn more: gsk.to/49XpQhi

#News for #investors and #media: We have announced that China’s health authority has approved one of our therapies for use in adults with asthma. Learn more here: gsk.to/4pQb3e1

We’ve announced an agreement to acquire RAPT Therapeutics. Find out more: gsk.to/4qwhWT9

Innovation starts when we stop to listen. Patients' experiences fuel our innovation, inspiring us to help people live happier, fuller lives. 🎥 Hear from the people who drive our purpose. #AheadTogether #JPM2026 #JPM26

#News for #Investors and #Media: The European Commission (EC) has approved a new prefilled syringe presentation of one of our vaccines. 👉 Learn more: gsk.to/3LvBgAu

#News for #investors and #media: We’ve just announced data from our pivotal phase III clinical programmes for chronic hepatitis B (CHB). This marks an important step towards addressing the global burden of CHB. Learn more: gsk.to/49HDLZM

#News for #investors and #media: A new therapy for two respiratory diseases has received approval from Japan’s health authority. Learn more here: gsk.to/3Lm8ZfI

#News for #investors and #media: We have announced that China’s health authority has approved one of our therapies for use in adults with a respiratory disease. Learn more here: gsk.to/4jqC3PO

Happy New Year from all of us! 🎉 As we step into 2026, our commitments remain strong. We're excited to continue on our journey to get ahead of disease together. What are you looking forward to achieving in 2026?

Season’s greetings from us at GSK to you! 🎄 May your day be filled with peace, happiness and special moments shared with those closest to you ✨

From our network to yours, we’re wishing you a happy holiday season from across the globe! Dive into the festive spirit and hear directly from our manufacturing teams who ensure our vital medicines and vaccines reach patients, even during this special time of year.👇

A new therapy for a respiratory disease has received approval today from the US Food and Drug Administration (FDA). For more information, visit: gsk.to/3KOUZLg

We're leaving #ASH25 filled with even more inspiration and determination to bring innovative treatment options to patients living with challenging blood cancers. Watch to see how our team engaged at this year’s meeting! 🎥 🩸

#News for #Media and #Investors: Today, we are announcing that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new therapy to treat two respiratory diseases. For more information, visit: www.gsk.com/en-gb/

At The Washington Post Live Post Next: The Future of Cancer event, Hesham Abdullah, Global Head of Oncology R&D shared what’s inspiring our vision to advance innovative research so those living with cancer can do more of what they love with those they care about most. Watch the video bit.ly/4qcE6ZT

#News for #investors and #media: We’re excited to share that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of two potential biologic treatments across three respiratory conditions. Learn more: gsk.to/48MZ1M2

#News for #investors and #media: The European Medicines Agency’s CHMP have issued a positive opinion on the expansion to a younger population for one of our vaccines. Access our website here: gsk.to/4aLrWTg

#News for #Media and #Investors: Today, we are announcing that one of our oral anti-infectives has been approved by the FDA. Learn more: www.gsk.com

#News for #Investors and #Media: Today we announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to an investigational antibody-drug conjugate in our oncology pipeline. Learn more here: gsk.to/4rFbiuy

Globally, more than 1 million people are diagnosed with a blood cancer each year. Through our latest research programmes, we are innovating for patients with blood cancers to help address their unmet needs. Watch to learn more. #ASH25

Outsmarting cancer demands focus 🔍 That’s why we’re channelling our science and technology where it can make the biggest difference for people living with cancer. Catch us at #ASH25 this weekend!

We’re looking forward to being on the ground at #ASH25 this weekend, presenting our latest progress in blood cancer research. What are you most excited for during this year’s congress? 👇

#News for #investors and #media: We are pleased to present new data from our #bloodcancer pipeline and portfolio at #ASH25. Learn more: gsk.to/4oKX2xX

2000 ➡️ 2025: celebrating 25 years of partnership with the @who.int on the Global Programme to Eliminate Lymphatic Filariasis (GPELF). 🔗 Find out more about the impact of the GPELF, here: gsk.to/4iwJ2X4

“More years in life, and more life in those years." That's what drives our research for people living with multiple myeloma 🧡 Our GSK experts explore what multiple myeloma is, the challenges patients face, and the potential impact of our research. 🎥 Watch the conversation: bit.ly/4rfYhaC

Every day infections are becoming harder to treat. The solutions exist. The challenge is acting fast enough, together, to make them count. Hear from experts from across science and healthcare on how we can get ahead of AMR if we act together, now.

COPD affects over 390 million people globally, significantly impacting patients like Val and their families. This #WorldCOPDDay2025 highlights the urgent need for earlier intervention to improve lives.

We’re announcing a major research programme with the Fleming Initiative to find new ways to get ahead of #AMR. We’re combining scientific expertise with cutting-edge AI technology, including funding for around 50 dedicated UK scientific and academic positions: gsk.to/4r4CrqD

We’re proud to join industry leaders and key policymakers at the #SilverEconomyForum in Manchester to discuss how we can foster trust in science to get ahead of disease and build more resilient societies. Watch this video to learn more about our approach to unlocking the power of prevention 👇

#News for #investors and #media: At #TLM25 we’ll share new data from our advancing hepatology pipeline - with 21 abstracts covering CHB, MASH, ALD and PBC. We remain committed to addressing the global burden of liver disease. Learn more: gsk.to/3WJNqIa

"One person doesn’t make a difference. We all come together, and we make it happen.” From facing cancer to co-founding the Multiple Myeloma Research Foundation, Kathy Giusti has made a huge difference to the lives of so many living with cancer. 🎥 Watch more: gsk.to/4nfiSJ7

Today we announce our Q3 2025 results, with another quarter of strong performance and upgraded guidance for 2025. Hear more from our CEO Emma Walmsley ⤵️ More information for media and investors: gsk.com $GSK #Q3Results

#News for #investors and #media: Today we announced an agreement with Empirico to add to our pipeline in COPD and potentially other inflammatory respiratory diseases. Find out more: gsk.to/4oF5Vt6

#News for #Investors and #Media: Today we announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to an investigational antibody-drug conjugate in our oncology pipeline. Learn more here: gsk.to/4hwnHfz

#News for #investors and #media: Today we announced an agreement with Syndivia to add to our growing oncology pipeline in prostate cancer. Find out more: gsk.to/4nrTYFX

#News for #Investors and #Media The US Food and Drug Administration (FDA) has approved our therapy to treat an incurable and challenging blood cancer. For more information, visit: www.gsk.com

We’re at #IDWeek2025 because infectious diseases remain one of the greatest public health challenges, responsible for one in six deaths worldwide. Many are still overlooked, and rising resistance is making treatment options less effective. ➡️ Want to learn more? www.gsk.com/en-gb/innova...

#News for #investors and #media: We’ve just announced data from our pivotal phase III clinical programme for a metered dose inhaler (MDI): gsk.to/4nkQipr

Together with ViiV Healthcare, we’re investing a total of £6m in the Global Fund, to help them fund locally led programmes that are tackling the high burden of HIV, tuberculosis and malaria in lower income countries.

#News for #Investors and #Media: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for a new prefilled syringe presentation of one of our vaccines. Learn more: gsk.to/47egZpR

#News for #Media and #Investors: Today, with Spero, we are sharing an update on the Phase III trial results of one of our investigational oral anti-infectives, presented during #IDWeek2025 in Atlanta. Learn more: gsk.to/47h8tGN

Understanding the challenges faced by those living with gynaecologic cancers is key to driving change. Visit us at #ESMO25 to learn more about our Your Cancer Is Our Challenge survey and how we’re working to amplify patient voices and improve care. 🔗 Learn more: bit.ly/4h9h2YB

Globally, one in five people will be diagnosed with cancer in their lifetime. We’re working to change outcomes for patients facing that reality. By advancing innovative oncology research, we’re aiming to redefine what’s possible in cancer care. ➡️ Find us at #ESMO25 this week to learn more.

At the @worldhealthsummit.bsky.social, we came together with @savechildrenuk.bsky.social to explore the role of partnerships in tackling evolving global health challenges. Collaboration is key for innovation and access to healthcare. Learn more in our impact report: gsk.to/474wYXt

#News for #Investors and #Media: Data presented at #EACS2025 by our specialist HIV company, ViiV Healthcare, offer a deeper understanding of therapy options & could help individuals & their healthcare providers make more fully informed choices about their HIV care. Find out more: gsk.to/4qacmpF

We believe in the power of vaccines to protect billions.

We believe HIV has a past but not a future.